Zobrazeno 1 - 7
of 7
pro vyhledávání: '"John Scholler"'
Autor:
Jamie E. DeNizio, Yan Wang, Simon F. Lacey, Vijay Bhoj, Tyler J. Reich, In-Young Jung, Regina M. Young, David L. Porter, John Scholler, Minnal Gupta, Julie K. Jadlowsky, Carl H. June, Todd Yoder, Christopher J. Ott, Megan M. Davis, Kathleen M. Haines, Irina Kulikovskaya, Golnaz Vahedi, Katherine T. Marcucci, Weimin Kong, Jun Xu, J. Joseph Melenhorst, John K. Everett, Joseph A. Fraietta, Marcela V. Maus, Erik F. Williams, Bruce L. Levine, Wenliang Wang, James E. Bradner, Rahul M. Kohli, Alexander Dimitri, Frederic D. Bushman, Maria Fasolino
Publikováno v:
J Clin Invest
Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of T cell deficiencies that hamper the expansion, persistence, and effector function of these cells. We u
Publikováno v:
J Cancer Res Clin Oncol
PURPOSE: Although adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has shown durable clinical efficacy in patients with CD19(+) B-cell malignancies, the application of this approach to solid tumors is challenging. The goa
Autor:
Neil E. Wilson, Aparna Bhaduri, Fang Liu, Ansuman T. Satpathy, Howard Y. Chang, Eric Perkey, Khatuna Gabunia, John Scholler, Ivan Maillard, Thomas J. Montine, Arnold R. Kriegstein, Avery D. Posey, Vijay Bhoj, Denis Migliorini, Ravinder Reddy, Carl H. June, Mohammad Haris, Kevin R. Parker, Puneet Bagga, Kathryn E. Yost, Suyash Mohan
Publikováno v:
Cell, Vol. 183, No 1 (2020) pp. 126-142.e17
Cell, vol 183, iss 1
Cell
Cell, vol 183, iss 1
Cell
CD19-directed immunotherapies are clinically effective for treating B cell malignancies but also cause a high incidence of neurotoxicity. A subset of patients treated with chimeric antigen receptor (CAR) Tcells or bispecific Tcell engager (BiTE) anti
Autor:
Vania Aikawa, Christopher A. Hunter, Miroslaw Kozlowski, Jennifer J.D. Morrissette, Michael Klichinsky, David L. Porter, Farzana Nazimuddin, David M. Barrett, John Scholler, David A. Christian, J. Joseph Melenhorst, Michael Kalos, Saar Gill, Stephan A. Grupp, Saad S. Kenderian, Carl H. June, Marco Ruella, Olga Shestova, Simon F. Lacey, Jessica Perazzelli, Ted J. Hofmann
Publikováno v:
Journal of Clinical Investigation. 126:3814-3826
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative rel
Autor:
Prachi R. Patel, Megan M. Davis, Joseph A. Fraietta, David M. Barrett, Simon F. Lacey, John Scholler, John Leferovich, Selene Nunez-Cruz, Stephan A. Grupp, Felipe Bedoya, J. Joseph Melenhorst, Michael C. Milone, Saba Ghassemi, Bruce L. Levine, Roddy S. O’Connor, Stefan Lundh, Changfeng Zhang, Carl H. June
Publikováno v:
Cancer Immunol Res
The success of chimeric antigen receptor (CAR)–mediated immunotherapy in acute lymphoblastic leukemia (ALL) highlights the potential of T-cell therapies with directed cytotoxicity against specific tumor antigens. The efficacy of CAR T-cell therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11fa33a7eb338dcda0c64f8c10178580
https://europepmc.org/articles/PMC8274631/
https://europepmc.org/articles/PMC8274631/
Autor:
Christopher L. Nobles, David M. Barrett, Regina M. Young, Carl H. June, David E Ambrose, Stephan A. Grupp, Bruce L. Levine, Prachi R. Patel, Jun Xu, Hans Bitter, Frederic D. Bushman, Irina Kulikovskaya, Farzana Nazimuddin, Olga Shestova, Simon F. Lacey, Joseph A. Fraietta, Shannon L. Maude, J. Joseph Melenhorst, Vijay Bhoj, Tyler J. Reich, Michael Klichinsky, Terry J. Fry, John Scholler, Saar Gill, Marco Ruella, Elena Orlando
Publikováno v:
Nature medicine. 24(10)
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19(-) leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufac
Autor:
John Scholler, Edmund K. Moon, Yangbing Zhao, Andrea L. Brennan, Carl H. June, Bruce L. Levine, Xiaojun Liu, Steven M. Albelda, Chrystal M. Paulos, Richard G. Carroll, Carmine Carpenito, Anne Chew
Redirecting T lymphocyte antigen specificity by gene transfer can provide large numbers of tumor-reactive T lymphocytes for adoptive immunotherapy. However, safety concerns associated with viral vector production have limited clinical application of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73ac7d41ecd46011f540ff72a5a3e380
https://europepmc.org/articles/PMC2982929/
https://europepmc.org/articles/PMC2982929/